Clinical trial results for
advanced esophageal
squamous cell cancer
For previously untreated adults with
advanced or metastatic esophageal
squamous cell cancer (ESCC)
Clinical trial results for
advanced esophageal
squamous cell cancer
For previously untreated adults with
advanced or metastatic esophageal
squamous cell cancer (ESCC)
Actor portrayals.
OPDIVO + YERVOY is not approved for people younger
than 18 years of age.
In a clinical trial of 649 people with previously untreated advanced or metastatic esophageal squamous cell cancer, 325 people were given OPDIVO + YERVOY and 324 people were given chemotherapy. The chemotherapy used in this clinical trial was fluorouracil and cisplatin.
In the clinical trial, people given OPDIVO + YERVOY had a 22% lower risk of dying than those given chemotherapy alone.
Half the people were alive
Half the people were alive
OPDIVO + YERVOY |
Chemotherapy |
Tumors disappeared completely (complete response)
Tumors shrank (partial response)
Tumors shrank or disappeared completely (overall response)
Words to know
Overall response rate is the percentage of patients who responded to treatment. These patients saw their tumors either shrink or disappear completely.
Partial response is when a tumor reacts to treatment and shrinks.
Complete response is when a tumor reacts to treatment and disappears completely. This is the disappearance of any measurable tumors in response to treatment. This does not mean the cancer has been cured.
OPDIVO + YERVOY will not work for everyone. Individual results may vary.
See your recommended treatment plan and what to expect from an infusion
For previously untreated adults with advanced or metastatic esophageal squamous cell cancer (ESCC)
OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults with cancer of the tube that connects your throat to your stomach (esophageal cancer) when your cancer is a type called squamous cell carcinoma and cannot be removed with surgery (advanced) or has spread to other parts of the body (metastatic), and you have not already had treatment for your advanced or metastatic esophageal cancer.
OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.
It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.
It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.